Diabetic Macular Edema Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Mylan, Novartis, Ocuphire, Opthea, Oxurion, Rezolute, Roche, YD Life Science, AbbVie, Allgenesis, AsclepiX, Celltrion, Exonate, Graybug Vision, KalVista

DelveInsight's "Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast 2032" report provides comprehensive insights into the disease landscape, encompassing historical and forecasted epidemiological data, along with an analysis of the Diabetic Macular Edema market. The report offers valuable information regarding market size, share, emerging trends, and growth prospects across the seven major markets (7MM), including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Additionally, the report delves into emerging therapies for Diabetic Macular Edema, providing insights into current treatment methodologies, individual therapy market shares, and a comprehensive evaluation of the market size, spanning from 2019 to 2032. It assesses the existing treatment practices and algorithms for Diabetic Macular Edema, investigates the key factors influencing market growth, identifies barriers, and highlights unmet medical needs. This comprehensive analysis aims to pinpoint opportunities and gauge the market's inherent potential to address the critical aspects of Diabetic Macular Edema management.

Learn How the Diabetic Macular Edema Market is Evolving with the Ongoing Developments @ Diabetic Macular Edema Market Outlook

Diabetic Macular Edema: An Overview

Diabetic Macular Edema (DME) is triggered by diabetic retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in developed and other developing countries. Common signs and symptoms include dark spots like a smudge on glasses or gaps that may appear in the vision, blurred vision, double vision, colors can fade, or the affected person may find bright light or glare difficult.

All people with Type 1 or Type 2 diabetes are at risk for DR and DME. The risk of developing DR or DME increases significantly the longer a person has diabetes. The American Academy of Ophthalmology (AAO) estimates that nearly 80% of patients with Type 1 diabetes will have developed DR after living with diabetes for 15 years. There are 50% chance that patients with Type 2 diabetes will develop DR after living with diabetes for around 20 years.

Diabetic Macular Edema diagnosis is clinically performed by fundoscopy; when the center of the macula (fovea centralis) is thickened or swollen, this is referred to as clinically significant central-involved macular edema (CI-CSME). It is referred to as a clinically significant non-central-involved macular edema (NCI-CSME) when it is unaffected.

Diabetic Macular Edema Market Key Facts

• Diabetic Macular Edema market size in the 7MM was ~USD 2.9 billion in 2021, which is expected to grow by 2032.
• In the United States, the total number of prevalent cases of Diabetic Macular Edema was 1,026,000+ in 2020.
• In 2020, the total prevalent cases of Diabetic Macular Edema were 641,000+ in EU-5.
• In Japan, the total number of prevalent cases of Diabetic Macular Edema was 194,000+ in 2020.
• Findings from various secondary studies suggest that Diabetic Macular Edema affects more males as compared to females, and is more prevalent in the elderly population. 

Get Exclusive Data and Key Insights Shaping the Market Dynamics @ Diabetic Macular Edema Market Trends

Diabetic Macular Edema Therapeutics Analysis

Treatment mainly involves the usage of anti-VEGF Drugs, corticosteroids, and Laser photocoagulation. Nonsteroidal anti-inflammatory drugs (NSAIDs), in the form of eye drops, are sometimes used either before or after cataract surgery to prevent the development of macular edema. Currently, intravitreal anti-VEGF agents are the preferred first-line treatment for Diabetic Macular Edema. The three most used anti-VEGF drugs are Avastin, Eylea, and Lucentis. These drugs block the activity of VEGF and slow the progress of macular edema. Corticosteroids are mostly a second-line treatment option. These anti-inflammatory drugs are usually administered via eye drops, implants, or injections of sustained-release corticosteroids into or around the eye. US FDA-approved sustained-release corticosteroid implants for more serious or longer-lasting conditions are Ozurdex, Retisert, and Iluvien.

The Diabetic Macular Edema market is expected to grow owing to the increase in diabetes cases mainly due to the aging population and sedentary lifestyle, expected entry of emerging therapies having similar efficacy and safety to current standard of care with less frequent requirement of injections, addressing barriers to screening and personalization of treatment.

Several major pharma and biotech companies are developing therapies for Diabetic macular edema. Some of the drugs in the pipeline include Beovu (brolucizumab) (Novartis), Faricimab (Roche), KSI-301 (Kodiak Sciences), ADVM022 (Adverum Biotechnologies),APX3330 (Ocuphire Pharma), THR-149 (Oxurion), UBX1325 (Unity Biotechnology) and several others. Currently, Mylan Pharmaceuticals is leading the therapeutics market with its Diabetic macular edema drug candidates in the most advanced stage of clinical development.

Diabetic Macular Edema Therapeutic Advancements and Emerging Treatments:

• Diabetic Macular Edema Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Adverum Biotechnologies, Allergan (now part of AbbVie), Allergo Ophthalmics, Allgenesis Biotherapeutics, Ascentage Pharma, AsclepiX Therapeutics, Bausch Health, Celltrion, Clearside Biomedical, Exonate, Graybug Vision, KalVista Pharmaceuticals, Kodiak Sciences, MingSight Pharmaceuticals, Molecular Partners, Mylan Pharmaceuticals, Novartis, Ocuphire Pharma, Opthea, Oxurion, Rezolute, Roche, and YD Life Science, and many others, are actively engaged in developing novel drugs for potential market entry.
• Diabetic Macular Edema Emerging and Marketed Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Diabetic Macular Edema. Some of the emerging therapies in the pipeline include ADVM-022 (Adverum Biotechnologies), GB-102 (Graybug Vision), Faricimab/RG 7716 (Roche), Beovu/RTH258/ brolucizumab) (Novartis), KVD001 (KalVista Pharmaceuticals), APX3330 (Ocuphire Pharma), THR-149 (Oxurion), YD-312 (YD Life Science), LKA651 (Novartis), Abicipar (Allergan/AbbVie/Molecular Partners), Luminate (ALG-1001/Risuteganib) (Allergo Opthalmics/ Bausch Health), KSI-301 (Kodiak Sciences), Xipere (CLS-TA) (Clearside Biomedical), and others.

Recent Developments in the Diabetic Macular Edema Market

• In January 2022, the United States Food and Drug Administration (US FDA) approved Roche's VABYSMO for treating Diabetic Macular Edema and neovascular (wet) age-related macular degeneration.
• In June 2022, Novartis announced the approval of BEOVU (brolucizumab) for the treatment of Diabetic Macular Edema.

Discover Significant Progress and Start Making Informed Decisions @ Clinical, Commercial, and Regulatory Activities in the Diabetic Macular Edema Market

Diabetic Macular Edema Market Growth Factors and Associated Trends

The Diabetic Macular Edema (DME) market within the seven major markets (7MM) faces a dynamic landscape influenced by a myriad of drivers and barriers. The increasing prevalence of diabetes mellitus serves as a primary driver propelling the growth of the Diabetic Macular Edema market. As diabetes continues to surge globally, the incidence of Diabetic Macular Edema, a common diabetic complication affecting the eyes, escalates in tandem. Moreover, technological advancements in diagnostic tools and treatment modalities, such as anti-VEGF therapies and sustained-release drug delivery systems, have significantly enhanced patient outcomes, fostering market growth. Additionally, the expanding geriatric population, particularly in developed economies, contributes to the rising Diabetic Macular Edema cases, given the higher prevalence of diabetes in older age groups.

However, despite these drivers, the market encounters several barriers that impede its growth trajectory. One significant challenge is the high cost associated with advanced therapies and treatments for Diabetic Macular Edema. Access to these treatments might be limited due to financial constraints, especially in emerging economies, thereby hindering market expansion. Moreover, the regulatory landscape poses hurdles in terms of approvals and market access for novel therapies, leading to delays and limitations in their availability. Furthermore, the complexity of the disease itself presents a challenge, as Diabetic Macular Edema often requires long-term management and personalized treatment approaches, adding to the burden on healthcare systems and patients.

Diabetic Macular Edema Market

The report's market outlook section offers a comprehensive understanding of the historical, present, and projected market size. It scrutinizes the influence of existing and upcoming pipeline therapies for Diabetic Macular Edema. Moreover, it conducts a thorough evaluation of the factors driving and hindering the Diabetic Macular Edema market, highlighting unmet needs and emerging technologies poised to shape the market's dynamics in the foreseeable future.

The report meticulously outlines the market trends concerning each marketed Diabetic Macular Edema drug and mid to late-stage pipeline therapies. This evaluation gauges their impact by considering various aspects such as the annual cost of therapy, Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competitive landscape among therapies, brand value, and their collective influence on the market dynamics.

Discover the Anticipated Evolution and Growth of the Market @ Diabetic Macular Edema Therapeutics Market Forecast

Diabetic Macular Edema Epidemiology Assessment

The epidemiology section offers valuable insights into the historical, present, and anticipated trends in Diabetic Macular Edema epidemiology across the seven major countries (7MM) from 2019 to 2032. This section aims to identify the factors contributing to current and projected Diabetic Macular Edema epidemiological patterns by examining diverse studies and research findings. Additionally, it furnishes a comprehensive analysis of diagnosed and prevalent patient populations, and future projections, and incorporates perspectives from key opinion leaders to enrich the understanding of this disease landscape.

The Report Covers the Diabetic Macular Edema Epidemiology, Segmented as -

• Total Prevalent Cases of Diabetic Macular Edema in the 7MM [2019–2032]
• Gender-specific Diagnosed Cases of Diabetic Macular Edema in the 7MM [2019–2032]
• Total Diagnosed Cases of Diabetic Macular Edema in the 7MM [2019–2032] 
• Age-Specific Diagnosed Cases of Diabetic Macular Edema in the 7MM [2019–2032]
• Treated cases of Diabetic Macular Edema in the 7MM [2019–2032]
• Subgroup-specific Diagnosed Cases of Diabetic Macular Edema in the 7MM [2019–2032]

Diabetic Macular Edema Drugs Uptake and Pipeline Development Activities

The drug uptake section concentrates on evaluating the adoption rate of newly launched or upcoming potential drugs within the Diabetic Macular Edema market during the study period. This analysis encompasses the assessment of drug uptake in the Diabetic Macular Edema market, patient adoption across different therapies, and the sales performance of each drug. Furthermore, the therapeutics assessment section facilitates a comprehensive comprehension of market dynamics by examining drug sales trends, identifying drugs with the highest adoption rates, and elucidating the reasons contributing to the widespread use of specific medications. Additionally, it conducts comparative analyses among Diabetic Macular Edema drugs, considering their sales performance and respective market shares.

The report encompasses comprehensive coverage of ongoing Diabetic Macular Edema pipeline development initiatives. It furnishes valuable insights into diverse therapeutic candidates at various developmental stages, elucidating the significant companies actively engaged in creating targeted treatments for Diabetic Macular Edema. Moreover, it conducts an in-depth analysis of recent advancements, including collaborations, acquisitions, mergers, licensing details, and patent information, providing a holistic view of emerging therapies within the field.

Reports Key Features and Analysis

• Study Period - 2019-32
• Forecast Period - 2023-32
• Geography Coverage - 7MM (United States, EU4 [Germany, Spain, Italy, France], the United Kingdom, and Japan)
• Market Size (by 2032) and Expected CAGR - Download the Sample PDF
• Major Players Shaping the Market Dynamics - Adverum Biotechnologies, Allergan (now part of AbbVie), Allergo Ophthalmics, Allgenesis Biotherapeutics, Ascentage Pharma, AsclepiX Therapeutics, Bausch Health, Celltrion, Clearside Biomedical, Exonate, Graybug Vision, KalVista Pharmaceuticals, Kodiak Sciences, MingSight Pharmaceuticals, Molecular Partners, Mylan Pharmaceuticals, Novartis, Ocuphire Pharma, Opthea, Oxurion, Rezolute, Roche, and YD Life Science, and many others.
• Emerging and Marketed Therapies Covered in the Report - ADVM-022 (Adverum Biotechnologies), GB-102 (Graybug Vision), Faricimab/RG 7716 (Roche), Beovu/RTH258/ brolucizumab) (Novartis), KVD001 (KalVista Pharmaceuticals), APX3330 (Ocuphire Pharma), THR-149 (Oxurion), YD-312 (YD Life Science), LKA651 (Novartis), Abicipar (Allergan/AbbVie/Molecular Partners), Luminate (ALG-1001/Risuteganib) (Allergo Opthalmics/ Bausch Health), KSI-301 (Kodiak Sciences), Xipere (CLS-TA) (Clearside Biomedical), and many others.

For In-depth Insights, key Report Offerings TOC, Access the Sample PDF File @ Diabetic Macular Edema Therapeutics Market Outlook and Forecast

Related Reports:

• Diabetic Macular Edema Epidemiology Forecast

The Diabetic Macular Edema Epidemiology Forecast report delivers an in-depth understanding of Diabetic Macular Edema, and historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

• Diabetic Macular Edema Pipeline Insight

The Diabetic Macular Edema Pipeline Insight report provides comprehensive insights about major pharma and biotech companies and emerging drugs in the Diabetic Macular Edema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Healthcare Consulting and Market Research Services by DelveInsight

Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @ Healthcare Market Research Services

Discover how our tailored methodology ensures real-time evaluation of cancer therapy performance using Lead and Lag KPIs. Download our Oncology Product Assessment Case study!

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

Contact Information:

Shruti Thakur (Manager, Marketing and IB)

info@delveinsight.com

www.delveinsight.com

Connect with DelveInsight: LinkedIn | Facebook | Twitter